New Preliminary Findings on Potential Response Indicator of Rakuten Medical's Alluminox Treatment from Phase 2 Window of Opportunity Study at SNMMI 2023
Rakuten Medical, Inc.Rakuten Medical, Inc., a global biotechnology company developing and commercializing precision, cell targeting therapies based on its proprietary Alluminox™ platform, today announced that new interim evaluation data from the ASP-1929-103 study has been presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2023 Annual Meeting held from June 24 to 27.